FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2618325173> ?p ?o ?g. }

• W2618325173 endingPage "485" @default.
• W2618325173 startingPage "474" @default.
• W2618325173 abstract "RG7716 is a novel bispecific antibody that simultaneously binds vascular endothelial growth factor (VEGF) and another key angiogenic factor, angiopoietin 2. A phase I study of intravitreal RG7716 was conducted to evaluate single-dose and multiple-dose safety in patients with neovascular age-related macular degeneration (AMD).Open-label, single and multiple ascending-dose study.Twenty-four patients diagnosed with neovascular AMD with best-corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent) and refractory subfoveal choroidal neovascularization defined as leakage on fluorescein angiography or fluid on spectral-domain optical coherence tomography despite 3 or more intravitreal anti-VEGF treatments in the preceding 6 months.Single intravitreal doses of 0.5 mg, 1.5 mg, 3 mg, and 6 mg RG7716 were administered in stepwise dose-escalation groups, each with 3 patients. In the multiple-dose phase, 6 patients were enrolled and received 3 treatments each of 3 mg and 6 mg RG7716.Safety and tolerability, changes in baseline BCVA, and central subfield thickness (CST).There were no dose-limiting toxicities in either the single-dose or multiple-dose group. Treatment-emergent ocular adverse events were mild. There was a single withdrawal and 1 serious adverse event, both deemed to be unrelated to the study drug by principal investigators. In the combined single-dose groups and in the 6-mg multiple-dose group, BCVA increased from baseline to 28 days after the last dose administration by a median of 7 letters (range, 0-18 letters; n = 11) and 7.5 letters (range, 3-18 letters; n = 6), respectively. The corresponding median reduction from baseline in CST were 42 μm (range, -101 to 10 μm; n = 11) and -117 μm (range, -252 to -7 μm; n = 6), respectively. After multiple 3-mg RG7716 doses, no changes were observed in either BCVA (median, -0.5 letters; range, -9 to 8 letters; n = 6) or CST (median, -9 μm; range, -188 to -1 μm; n = 6).RG7716 was well tolerated and exhibited an overall favorable safety profile, with evidence of improvements in BCVA and anatomic parameters. These data support further evaluation of RG7716 in phase II trials." @default.
• W2618325173 created "2017-06-05" @default.
• W2618325173 creator A5010632648 @default.
• W2618325173 creator A5012964371 @default.
• W2618325173 creator A5016211526 @default.
• W2618325173 creator A5016588157 @default.
• W2618325173 creator A5017123309 @default.
• W2618325173 creator A5019521414 @default.
• W2618325173 creator A5024669016 @default.
• W2618325173 creator A5026046068 @default.
• W2618325173 creator A5030449236 @default.
• W2618325173 creator A5035600524 @default.
• W2618325173 creator A5037459780 @default.
• W2618325173 creator A5059171474 @default.
• W2618325173 creator A5061951511 @default.
• W2618325173 creator A5072070335 @default.
• W2618325173 creator A5083062288 @default.
• W2618325173 creator A5085965174 @default.
• W2618325173 creator A5076348133 @default.
• W2618325173 date "2017-11-01" @default.
• W2618325173 modified "2023-10-17" @default.
• W2618325173 title "Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration" @default.
• W2618325173 cites W1486264823 @default.
• W2618325173 cites W1783580437 @default.
• W2618325173 cites W1968189763 @default.
• W2618325173 cites W1992423971 @default.
• W2618325173 cites W1996171994 @default.
• W2618325173 cites W2008455196 @default.
• W2618325173 cites W2012772868 @default.
• W2618325173 cites W2032908349 @default.
• W2618325173 cites W2049624292 @default.
• W2618325173 cites W2059108446 @default.
• W2618325173 cites W2062143592 @default.
• W2618325173 cites W2066834504 @default.
• W2618325173 cites W2080886828 @default.
• W2618325173 cites W2081872783 @default.
• W2618325173 cites W2083043469 @default.
• W2618325173 cites W2085712747 @default.
• W2618325173 cites W2096097549 @default.
• W2618325173 cites W2096547439 @default.
• W2618325173 cites W2098409014 @default.
• W2618325173 cites W2114147340 @default.
• W2618325173 cites W2124415048 @default.
• W2618325173 cites W2128210855 @default.
• W2618325173 cites W2147358575 @default.
• W2618325173 cites W2152215024 @default.
• W2618325173 cites W2154073405 @default.
• W2618325173 cites W2161552330 @default.
• W2618325173 cites W2343042175 @default.
• W2618325173 cites W2406071855 @default.
• W2618325173 cites W2531065411 @default.
• W2618325173 cites W2543150770 @default.
• W2618325173 cites W295728857 @default.
• W2618325173 cites W4233230329 @default.
• W2618325173 cites W4250031098 @default.
• W2618325173 doi "https://doi.org/10.1016/j.oret.2017.03.003" @default.
• W2618325173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31047438" @default.
• W2618325173 hasPublicationYear "2017" @default.
• W2618325173 type Work @default.
• W2618325173 sameAs 2618325173 @default.
• W2618325173 citedByCount "60" @default.
• W2618325173 countsByYear W26183251732018 @default.
• W2618325173 countsByYear W26183251732019 @default.
• W2618325173 countsByYear W26183251732020 @default.
• W2618325173 countsByYear W26183251732021 @default.
• W2618325173 countsByYear W26183251732022 @default.
• W2618325173 countsByYear W26183251732023 @default.
• W2618325173 crossrefType "journal-article" @default.
• W2618325173 hasAuthorship W2618325173A5010632648 @default.
• W2618325173 hasAuthorship W2618325173A5012964371 @default.
• W2618325173 hasAuthorship W2618325173A5016211526 @default.
• W2618325173 hasAuthorship W2618325173A5016588157 @default.
• W2618325173 hasAuthorship W2618325173A5017123309 @default.
• W2618325173 hasAuthorship W2618325173A5019521414 @default.
• W2618325173 hasAuthorship W2618325173A5024669016 @default.
• W2618325173 hasAuthorship W2618325173A5026046068 @default.
• W2618325173 hasAuthorship W2618325173A5030449236 @default.
• W2618325173 hasAuthorship W2618325173A5035600524 @default.
• W2618325173 hasAuthorship W2618325173A5037459780 @default.
• W2618325173 hasAuthorship W2618325173A5059171474 @default.
• W2618325173 hasAuthorship W2618325173A5061951511 @default.
• W2618325173 hasAuthorship W2618325173A5072070335 @default.
• W2618325173 hasAuthorship W2618325173A5076348133 @default.
• W2618325173 hasAuthorship W2618325173A5083062288 @default.
• W2618325173 hasAuthorship W2618325173A5085965174 @default.
• W2618325173 hasBestOaLocation W26183251731 @default.
• W2618325173 hasConcept C118487528 @default.
• W2618325173 hasConcept C126322002 @default.
• W2618325173 hasConcept C141071460 @default.
• W2618325173 hasConcept C167734588 @default.
• W2618325173 hasConcept C197934379 @default.
• W2618325173 hasConcept C2776403814 @default.
• W2618325173 hasConcept C2776694085 @default.
• W2618325173 hasConcept C2777025900 @default.
• W2618325173 hasConcept C2777802072 @default.
• W2618325173 hasConcept C2778257484 @default.
• W2618325173 hasConcept C2778375690 @default.
• W2618325173 hasConcept C2780248432 @default.

• next